DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Amwill Health Care Ltd (AMWILL) share price today?

Amwill Health Care Ltd (AMWILL) is trading at ₹41.43 on the BSE, down 3.09% on the day. Source: DocStoX.

What is the PE ratio of Amwill Health Care Ltd?

Amwill Health Care Ltd has a price-to-earnings (PE) ratio of 7.7 in the Healthcare sector.

What is the market capitalisation of Amwill Health Care Ltd?

Amwill Health Care Ltd has a market capitalisation of approximately ₹86 crore.

Amwill Health Care Ltd

AMWILL·BSE·Healthcare

₹41.43▼ -1.32 (-3.09%)

Healthcare · Pharmaceuticals & Biotechnology

Debt-free and consistently profitable

Day₹40.60

₹43.49

52W₹29

₹7130%

Open

₹42.75

High

₹43.49

Low

₹40.60

Prev Close

₹42.75

Volume

19.2K

VWAP

₹42.06

Snapshot

Key fundamentals

Market Cap

₹86 Cr

P/E Ratio

7.73Cheap

P/B Ratio

1.06

EPS

₹5.36

Book Value

₹40.28

ROE

15.20%Strong

ROCE

28.00%Efficient

Dividend Yield

1.17%

Debt / Equity

0.00Low

Face Value

₹10.00

52W High

₹71.00

52W Low

₹28.91

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Buy

Narrow moatHigh uncertainty

Fair value estimate

₹53

▲ 28.5%upside

Trading at ₹41 — 28% below our estimate

BearFair valueBull

₹45₹53₹72

/100

Business quality — Solid

Growth 50Profitability 76Efficiency 100Valuation 100

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 28%)
Reasonably priced at 8× earnings
Promoters hold a controlling stake

How we got there

Fair value methods

Residual income

16% ROE fading to 12% over ~10 yrs, on ₹40 book

₹48

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹72

Analyst target

No analyst coverage

—

Blended fair value₹53

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 28%)
Reasonably priced at 8× earnings
Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

7.7Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

15.2%Strong

Above 15% is considered healthy for Indian equities

ROCE

28.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹86 Cr

P/B

1.06

EPS

₹5.36

Div Yield

1.17%

What changed

Recent changes

Foreign investors-1.2% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 7.7×

Growth

Strong

+18% rev CAGR

Profitability

Healthy

15.2% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹8.08L Cr

Trades16

VWAP₹42.06

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+17.6%

+21.8%

10Y

—

Profit

+55.9%

—

10Y

—

EPS

-82.3%

—

10Y

—

Profile

Pros

Company is almost debt free.
Stock is trading at 1.06 times its book value
Company has delivered good profit growth of 68.1% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 26.8%

Watch-outs

Cons

Company has high debtors of 168 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 1.16 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

71%

Promoter

Promoters

70.7%0.00

Public

26.4%+1.52

FII / FPI

0.0%-1.16

DII

0.0%0.00

Others

3.0%

Total shareholders

1,483-123 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter70.65%

Public26.37%

Others2.98%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2009, Amwill Health Care is in the wholesale trading of pharmaceutical products[1]